19
Repeat treatment (up to 3 treatment cycles) with BoNTA* is safe and well-tolerated at doses up to 260U Repeat treatment (up to 3 treatment cycles) with BoNTA* is safe and well-tolerated at doses up to 260U No neutralizing antibodies No neutralizing antibodies No benefit of placebo run-in  pool PNR and PR groups No benefit of placebo run-in  pool PNR and PR groups Although the 1° endpoint was not met, significant & clinically meaningful improvements were seen following BoNTA* vs placebo: Although the 1° endpoint was not met, significant & clinically meaningful improvements were seen following BoNTA* vs placebo:  Responder rates  Headache frequency No significant change in proportion of patients with ≥50% Decrease in HA Frequency, Number of Days of Acute HA Med Use, Number of Uses of Acute Meds, MIDAS, Headache Specific QOL No significant change in proportion of patients with ≥50% Decrease in HA Frequency, Number of Days of Acute HA Med Use, Number of Uses of Acute Meds, MIDAS, Headache Specific QOL Chronic Daily Headache – Safety & Results Mathew et al, Headache *Allergan, Botox®, USA

28
Conclusions Onset of effect occurred within 2 – 3 days following injection and lasted for months. Onset of effect occurred within 2 – 3 days following injection and lasted for months. Side effects are infrequent, mild and transient. Side effects are infrequent, mild and transient. Subjective and objective evidence for reduction in tear production. Subjective and objective evidence for reduction in tear production. Effectiveness needs to be established with a randomised clinical trial. Effectiveness needs to be established with a randomised clinical trial.